

# CSL Research Acceleration Initiative

Applications close 24<sup>th</sup> February 2026

## WHY COLLABORATE WITH CSL?



Funding of up to \$400,000 USD over 2 years



Access global capabilities and expertise  
CSL scientific champion assigned to provide industry guidance and help you leverage our global capabilities



Publish with CSL  
270+ publications with our collaborators since 2020



Accelerate  
Translation of your research into new therapies

CSL is a leading global biotech company delivering innovative therapies to help people with life-threatening conditions live full lives.

The CSL **Research Acceleration Initiative** supports early-stage biotechs and research organizations to fast-track the discovery of groundbreaking biotherapies.

Successful applicants can receive up to **\$400,000 USD in non-dilutive funding** over 2 years to advance their innovative programs.

Interested researchers are invited to:

- **Attend an information webinar (choose one of two sessions)**

Wednesday, 28 January 1:00PM AEDT – [Click to join](#)

Thursday, 5 February 2:00PM AEDT – [Click to join](#)

- **Submit enquiries, expressions of interest and requests for application instructions to:**

Name:

Email:

- **Submit** a non-confidential, 500-word abstract via the CSL online application portal by **24<sup>th</sup> February 2026**.

The 2026 Research Acceleration Initiative will focus on research proposals that align with a CSL **Therapeutic Area**. Please see over page for specific **Focus Areas**.

Therapeutic Areas



# CSL Research Acceleration Initiative

## Focus Areas

CSL is seeking applications that align with a CSL Therapeutic Area in the following Focus Areas

CSL™

### Transplant & Immunology

#### Novel first in class targets and drug concepts to treat immune-mediated diseases e.g.

- Strategies for targeting pathogenic T cell subsets
- Strategies for targeting disease-driving chemokine receptors
- Multi-specific approaches that enable multiple cell types/ pathways to be targeted to treat complex immune-mediated diseases
- Strategies for targeting stromal cells, senescence or inflamming

#### Indication focus

- Chronic immune mediated rheumatologic and dermatologic diseases
- Rare neuro-immune disorders

### Cardiovascular & Renal

#### Genetic rare renal diseases

Novel targets or therapeutic candidates for polycystic kidney disease autosomal dominant tubulointerstitial kidney disease and Alport syndrome

#### Autoimmune-mediated rare renal diseases

Novel targets or therapeutic candidates for autoimmune-mediated rare glomerular diseases and ANCA-associated vasculitis

#### Rare cardiovascular diseases

Novel targets or therapeutic candidates for inflammatory, autoimmune or genetic cardiomyopathies

Novel targets or therapeutic candidates for immune checkpoint inhibitor-induced myocarditis

### Hematology

#### Acute hemorrhage control and Patient Blood Management (PBM)

- Pro-hemostatic therapies for anti-platelet agent-associated hemorrhage and intracerebral hemorrhage
- Treatments for targeting and preventing hyperfibrinolysis- and vascular malformations-associated bleeding

#### Transformative therapies for Hemophilia A

- Next generation non-AAV-based gene therapy
- Oral protein or nucleic acid-based treatments

#### Iron metabolism

- Novel treatments for iron deficiency and anemia
- Novel formulation approaches: oral & intramuscular iron supplementation
- Novel therapies to treat iron overload conditions
- Disease modifying therapies for myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, myelofibrosis and myelodysplastic syndrome

#### Acute thrombotic conditions

Novel therapies applicable to a broad spectrum of acute thrombotic diseases including microangiopathies (TMAs; pan-treatment)

### Immunoglobulins

#### Patient Experience

- High concentration/low volume formulation technologies
- Improve ease of administration and decrease administration time for plasma-derived products
- Technologies that enable novel routes of administration for plasma-derived products

#### Novel Therapies for

- Primary and Secondary Immunodeficiency Disorders
- Alpha 1 Antitrypsin Deficiency

#### Optimization of human-derived Ig products

- Technologies that can optimize, supplement or replace human-derived products

### Oral Delivery

Technologies enabling systemic oral delivery of biologics (e.g. antibodies and other large proteins)

CSL is also interested in new uses for our existing products. If you have a proposal in this area, please e-mail **RAI@CSL.COM.AU** to discuss.